C-kit受体酪氨酸激酶抑制剂的研究进展
作者：许佳凤;方正;陈燕;马香军;韦萍;
Author：
收稿日期： 年卷（期）页码：2010,25(05):-618-621
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：C-kit受体;受体酪氨酸激酶抑制剂;抗肿瘤;综述
Key words：
基金项目：
中文摘要
综述了近年来已上市或处于临床研究阶段的小分子C-kit受体酪氨酸激酶抑制剂的分类及其代表化合物。
参考文献
[1]Yarden Y,Kuang WJ,Yang FT,et al.Human proto oncogene C kit:a new cell surface receptor tyrosine kinase for a unidenti-fied ligand[J].EMBO J,1987,6(11):33413351.
[2]Hitoshi K,Tohru T,ltaru M,et al.Neoplastic transformation of normal hematopoietic cells by constitutively activating mutationsof C kit receptor tyrosine Kinase[J].Blood,1996,88(3):9951004.
[3]Kanda Y,Okamoto S,Tauchi T,et al.Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase:Does body weight matter?[J].Ame J Hematol,2008,83(11):835839.
[4]Dickens E,Lewis F,Bienz N.Imatinib:a designer drug,anoth-er cutaneous complication[J].Clin Exper Dermatol,2009,34(5):603604.
[5]Jorge Cortes,Philippe Rousselot,Dong Wook Kim,et al.Dasat-inib induces complete hematologic and cytogenetic responses in patients with imatinib resistant or intolerant chronic myeloid leukemia in blast crisis[J].Blood,2007,109(8):32073213.
[6]Eley T,Luo FR,Agrawal S,et al.PhaseⅠStudy of the effcet of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects[J].J Clin Pharmac,2009,49(6):700709.
[7]Tiwari AK,Sodani K,Wang SR,et al.Nilotinib(AMN107,Ta-signa(R))reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters[J].Bioch Pharmac,2009,78(2):153161.
[8]Cheung CHA,Coumar MS,Hsieh HP,et al.Aurora kinase inhibi-tors in preclinical and clinical testing[J].Expert Opinion on In-vestigational Drugs,2009,18(4):379398.
[9]Hembrough TA,Chen X,Burke PA,et al.Inhibition of multiple myeloma tumor growth and FGFR3by the aurora angiogenesis inhibitor ENMD981693[J].Blood,2007,110(11):366A.
[10]Demetri GD,Van Oosterom AT,Garrett CR,et al.Efficacy and safety of sunitinib in patients with advanced gastrointestinal stro-mal tumour after failure of imatinib:a randomised controlled trial[J].Lancet,2006,368(9544):13291338.
[11]Huang M,Liu X,Du Q,et al.Inhibitory effects of sunitinib on ovalbumin induced chronic experimental asthma in mice[J].Chin Med J,2009,122(9):10611066.
[12]Alex Kiselyov,Konstantin V Balakin,Sergey E Tkachenko.VEGF/VEGFR signaling as a target for inhibiting angiogenesis[J].Expert Opinion on Investigational Drugs,2007,16(1):83107.
[13]Rixe O,Bukowski RM,Michaelson MD,et al.Axitinib treatment in patients with cytokine refractory metastatic renal cell canc-er:a phaseⅡstudy[J].Lancet Oncol,2007,8(11):975-984.
[14]Takahashi K,Saishin Y,Saishin Y,et al.Suppression and Re-gression of choroidal neovascularization by the multitargeted ki-nase inhibitor pazopanib[J].Arch Ophthalmol,2009,127(4):494499.
[15]Sonpavde Guru,Hutson,Thomas E.Pazopanib:A novel multitar-geted tyrosine kinase inhibitor[J].Curr Oncol Rep,2007,9(2):115119.
[16]Hos D,Bock F,Dietrich T,et al.Inflammatory corneal(lymph)angiogenesis is blocked by VEGFR tyrosine kinase inhibitor ZK261991,resulting in improved graft survival after corneal trans-plantation[J].Investigative Ophthalmology&Visual Sci,2008,49(5):18361842.
[17]Padera TP,Kuo AH,Hoshida T,et al.Differential response of primary tumor versus lymphatic metastasis to VEGFR2and VEGFR3kinase inhibitors cediranib and vandetanib[J].Molecul Canc Therap,2008,7(8):22722279.
[18]Goss G,Shepherd FA,Laurise S,et al.A phaseⅠand pharmaco-kinetic study of daily oral cediranib,and inhibitor of vascular en-dothelial growth factor tyrosine kinases in combination with cispl-atin and gemcitabine in patients with advanced non small cell lung cancer:A study of the National Can Institute of Canada Clin-ical Trials Group[J].Euro J Cancer,2009,45(5):782788.
[19]Cheng Y,Paz K.Tandutinib,an oral,small molecule inhinitor of FLT3for the treatment of AML and other cancer indications[J].Idruge,2008,11(1):4656.
[20]Nakamura K,Taguchi E,Miura T,et al.KRN951,a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine ki-nases,has antitumor activities and affects functional vascular properties[J].Cancer Res,2006,66(18):91349142.
[21]Taguchi E,Nakamura K,Miura T,et al.Anti tumor activity and tumor vessel normalization by the vascular endothelial growth fac-tor receptor tyrosine kinase inhibitor KRN951in a rat peritoneal disseminated tumor model[J].Cancer Sci,2008,99(3):623-630.
[22]Kim KB,Saro J,Moschos SS,et al.A phase I dose finding and bi-omarker study of TKI258(dovitinib lactate)in patients with ad-vanced melanoma[J].J Clinical Oncology,2008,26(15S):9026.
[23]Garton AJ,Crew APA,Franklin M,et al.OSI930:A novel se-lective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models[J].Cancer Res,2006,66(2):10151024.
[24]Coxon A,Bush T,Saffran D,et al.Broad antitumor activity in breast cancer xenografts by motesanib,a highly selective,oral in-hibitor of vascular endothelial growth factor,platelet derived growth factor,and kit receptors[J].Clin Cancer Res,2009,15(1):110118.
[25]Mahadevan D,Cooke L,Riley C,et al.A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors[J].Oncogene,2007,26(27):39093919.
[26]Kansal N,Silakari O,Ravikumar M,et al.Three dimentional pharmacophore modelling for c Kit receptor tyrosine kinase in-hibitors[J].Euro J Med Chem,2010,45:393404.
【关闭】
